Scientific Advisory Board
Timothy Springer, PhD
Co-founder, Scholar Rock®
Latham Family Professor at Harvard Medical School and Professor of Medicine at Children's Hospital Boston

For more information:
Springer Lab

Leonard Zon, MD
Co-founder, Scholar Rock®
Grousbeck Professor of Pediatric Medicine at Harvard Medical School, Director of the Stem Cell Program at Children's Hospital Boston, and HHMI Investigator

For more information:
Zon Lab

Barry Coller, MD
Physician in Chief, Vice President for Medical Affairs, and the David Rockefeller Professor, The Rockefeller University

For more information:
Coller Lab

Jeffrey S. Flier, MD
Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor
Former Dean of Harvard Medical School
Scott L. Friedman, MD
Professor of Medicine, Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai Hospital, New York

For more information:
Friedman Lab

Michael Gilman, PhD
CEO, Arrakis Therapeutics
CEO, Obsidian Therapeutics
Dr. Gilman is a scientist, general manager, biotech executive, and serial entrepreneur. He is currently Chair and CEO for Arrakis Therapeutics and CEO and Director for Obsidian Therapeutics. He also serves on the Board of Directors of X4 Pharmaceuticals and the SAB of FutuRx, an Israeli biotech accelerator. Previously, Dr. Gilman was Founder and CEO of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. Prior to Padlock, Dr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company’s development programs through clinical proof-of-concept. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-backed company focused on fibrosis and organ failure, where he was Founder and CEO. Prior to founding Stromedix in 2006, Dr. Gilman served as EVP, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, where he was EVP and CSO. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology.
Joan Massagué, PhD
Director, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center

For more information:
Massagué Lab

Daniel Rifkin, PhD
Charles Aden Poindexter Professor of Medicine, New York University Langone Medical Center

For more information:
Rifkin Lab

Lynn Sakai, PhD
Professor of Biochemistry & Molecular Biology, Oregon Health & Science University; Senior Investigator,Portland Shriners Research Center

For more information:
Sakai Lab

Akshay Vaishnaw, MD, PhD
EVP of Research & Development, Alnylam Pharmaceuticals, Inc.
Dr. Vaishnaw joined Alnylam in 2006, coming from Biogen, Inc. (now Biogen Idec Inc.), where he was most recently Senior Director, Translational Medicine. In his seven years at Biogen he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive™) for psoriasis. Akshay received his M.D. from the University of Wales College of Medicine, U.K., with Distinctions in Pathology and Medicine, and his Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Member of the Royal College of Physicians, U.K. In addition, Akshay has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease.
Shelia M. Violette, PhD
Entrepreneur in Residence, Atlas Venture
Dr. Violette was previously Vice President of Tissue Injury and Fibrosis Research at Biogen where she spearheaded a team of scientists conducting discovery research and developing translational approaches to advance programs into clinical development. From 2008 to 2012, Dr. Violette was Vice President of Research at Stromedix and led all research activities supporting the development of the anti-v6 antibody, STX-100. Dr. Violette has more than 20 years of industry experience advancing programs from early research to clinical development. She has provided strategic and operational leadership to multi-disciplinary teams of scientists and authored more than 80 manuscripts and patents. Dr. Violette has directed research and led therapeutic programs at several biotechnology companies including Repligen, Ariad, Stromedix and Biogen. She is currently an Entrepreneur in Residence at Atlas Venture, Cambridge, MA. Dr. Violette received her Ph.D. in Pharmacology from Yale University and carried out her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.
CONTACT  |  SITEMAP  | 
 |  SITE DESIGN
“Scholar Rock” is a registered trademark of Scholar Rock, Inc.  |  © 2017 Scholar Rock All Rights Reserved.
Back to Top
 

The site you are about to visit is maintained by another organization, which is solely responsible for its content. As we cannot control the content or privacy practices of any third-party websites, we encourage you to read the privacy policy of every website you visit.

Continue   Cancel